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Abstract
Objective: Increased translocator protein (TSPO), previously known as the
peripheral benzodiazepine receptor (PBR), in glial cells of the brain has been
used as a neuroinflammation marker in the early and middle stages of neurode-
generative diseases, such as Alzheimer’s disease (AD) and Dementia with Lewy
Bodies (DLB). In this study, we investigated the changes in TSPO density with
respect to late stage AD and DLB. Methods: TSPO density was measured in
multiple regions of postmortem human brains in 20 different cases: seven late
stage AD cases (Braak amyloid average: C; Braak tangle average: VI; Aged 74–
88, mean: 83  5 years), five DLB cases (Braak amyloid average: C; Braak tan-
gle average: V; Aged 79–91, mean: 84  4 years), and eight age-matched nor-
mal control cases (3 males, 5 females: aged 77–92 years; mean: 87  6 years).
Measurements were taken by quantitative autoradiography using [3H]PK11195
and [3H]PBR28. Results: No significant changes were found in TSPO density
of the frontal cortex, striatum, thalamus, or red nucleus of the AD and DLB
brains. A significant reduction in TSPO density was found in the substantia
nigra (SN) of the AD and DLB brains compared to that of age-matched healthy
controls. Interpretation: This distinct pattern of TSPO density change in late
stage AD and DLB cases may imply the occurrence of microglia dystrophy in
late stage neurodegeneration. Furthermore, TSPO may not only be a microglia
activation marker in early stage AD and DLB, but TSPO may also be used to
monitor microglia dysfunction in the late stage of these diseases.
Introduction
Translocator protein 18 kDa (TSPO), previously known
as the peripheral benzodiazepine receptor (PBR), is
located on the outer membrane of mitochondria and is
a part of mitochondrial permeability transition pore.1
Outside of the central nervous system, it is ubiquitously
expressed in the kidneys, heart, adrenal gland, and
reproductive tract2,3; in the brain it is expressed at a
low level in the resting glial cells.2 TSPO is believed to
be involved in the synthesis of steroids and the translo-
cation of cholesterol from the outer to the inner mito-
chondria membrane.4 TSPO is also involved in the
regulation of cell death,1 cell proliferation, and
inflammation.5 TSPO density has been found to be
increased in many neurological diseases such as
ischemic stroke, multiple sclerosis, amyotrophic lateral
sclerosis, encephalitis, and frontotemporal dementia.6
The upregulation of TSPO is often accompanied by
microglial changes from resting to activated morphology
and the secretion of cytokines which can induce tissue
inflammatory response; hence TSPO is currently
accepted as a neuroinflammation marker.
TSPO density in the human AD and DLB brain has
been extensively explored by PET studies using [11C]
PK11195,7–9 [11C]DAA1106,10 [11C]vinpocetine,11 and
[11C]PBR28;12–15 and by autoradiography studies using
[3H]PK11195,16,17 [3H] DAA1106,17 and [125I]
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DAA1106.18 In these studies early stage patients with
mild to moderate cognitive impairment (clinical dementia
rate (CDR) 1 and 2) were usually recruited and increases
in TSPO density were often found in multiple brain
regions.7,10,15 Two studies showed no significant change
in TSPO density between aged AD (CDR unknown) and
the age-matched control brain.9,11 Because it is a marker
of microglia activation, increases in TSPO density in early
stage AD may reflect the involvement of microglia-medi-
ated neuroinflammation in the pathogenesis of AD,19
although the enhanced phagocytosis by activated micro-
glia has been reported to have a protective effect.20,21
Microglial dystrophy has been recently observed in the
AD brain; this is thought to play a key role in the patho-
genesis of AD.22–28 Both Tau pathology and amyloid beta
pathology have been reported to promote microglial dys-
trophy,29,30 which may occur via telomere shorten-
ing.29,31,32 Although microglial dystrophy is closely related
to AD stage, TSPO density in late stage AD and DLB has
not been well documented until now. In this communica-
tion, we hypothesize that DLB and AD patients have
more microglial dystrophy than healthy controls and
TSPO PET may be useful for measuring late stage micro-
glia dystrophy in DLB and AD patients. To explore the
relationship between TSPO density change and microglial
dystrophy, we systematically studied a group of late stage
AD and DLB cases and measured TSPO density in multi-
ple brain regions using quantitative autoradiography with
two radioligands [3H]PK11195 and [3H]PBR28.
Materials and Methods
Ethics statement
After death, the written consent of the next of kin was
obtained for brain removal per local Ethical Committee
procedures (Washington University Institutional Review
Board, Washington University School of Medicine). Use
of this tissue for the postmortem receptor autoradiogra-
phy study was approved by the Charles F. and Joanne
Knight Alzheimer’s Disease Research Center (Knight
ADRC) Leadership Committee.
Chemicals and radioligands
Chemical reagents and the standard compounds were
purchased from Sigma-Aldrich (St. Louis, MO) and
Tocris (Ellisville, MO). [3H]PK11195 (69.9 Ci/mmol) was
purchased from Perkin Elmer Life Sciences (Boston, MA)
and [3H]PBR28 (80 Ci/mmol) was purchased from Amer-
ican Radiolabeled Chemicals (St Louis, MO).
Postmortem human brain cases
Clinically and neuropathologically well-characterized
human brain tissues were obtained from the Knight
ADRC at Washington University School of Medicine
including: seven AD (1 male, 6 females) aged 74–88
(mean: 83  5) years at death, five DLB (2 males, 3
females) aged 79–91 (mean: 84  4) years at death,
and eight age-matched normal control cases (3 males, 5
females) aged 77–92 (mean: 87  6) years at death.
Dementia level was evaluated by CDR. Alzheimer dis-
ease pathological changes were assessed using Braak
staging.33,34 Stages of amyloid beta deposition refer to
initial deposits in the basal neocortex (A), deposits
extended into the association areas of the neocortex
(B), and heavy deposition throughout the entire cortex
(C). Stages of neurofibrillary pathology correspond to
transentorhinal (I–II), limbic (III–IV), and neocortical
(V and VI). There is no significant difference between
the average age and post mortem interval time among
these three groups; whereas all the AD and DLB cases
show a heavy burden of amyloid beta (Average: C) and
neurofibrillary tangles (NFTs) (Average: VI for AD; V
for DLB) and are significantly different from that of
age-matched control cases (Average amyloid beta: A;
NFTs: II). There exist significant differences in the
brain weight and the CDR between the control cases
and the AD or DLB cases. Detailed information on the
clinical and pathological features is summarized in
Table 1.
Tissue collection
Brains were removed at the time of autopsy and the right
hemisphere was coronally sectioned and snap-frozen by
contact with Teflon-coated aluminum plates cooled in
liquid nitrogen vapor. Tissue blocks were subsequently
placed in airtight zip-lock plastic bags and stored
at  80°C until used. Microscopic examination to estab-
lish neuropathology was performed using established rat-
ing scales. For autoradiography studies, frozen coronal
sections (20 µm) were cut with a Microm cryotome and
mounted on Superfrost Plus glass slides (Fisher Scientific,
Pittsburgh, PA) from the following brain regions: the stri-
atal regions, containing the caudate and putamen, of the
frontal cortex, and the middle brain containing the sub-
stantia nigra (SN), the red nucleus (RN), and the thala-
mus (Th). Data from 2–4 sections were averaged to
determine total binding. Nonspecific binding was defined
by the average of two adjacent sections for the two radi-
oligands.
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Quantitative autoradiography protocol
Sections on slides were incubated in an open staining jar
with the respective radiotracer for 30 min as detailed
below; slides were then rinsed five times at 1 min inter-
vals with ice-cold buffer, then air dried. This protocol
results in a free radioligand concentration loss < 5%, as
described previously.35,36
TSPO binding
TSPO was labeled with [3H]PK11195 and [3H]PBR28.
Briefly, adjacent brain sections were incubated for 30 min
in buffer solution at room temperature with the addition
of 2 nmol/L [3H]PK11195 and [3H]PBR28, respectively.
Nonspecific binding was determined from incubating the
slides in the presence of 1 µmol/L PBR28 for [3H]
PK11195, and 1 µmol/L PK11195 for [3H]PBR28.
Quantification of total radioactivity
Slides were made conductive by coating the free side with
a copper foil tape. Slides were then placed in the sample
holder and loaded into a gas chamber containing a mix-
ture of argon and triethylamine (Sigma-Aldrich) as part
of a gaseous detector system, the Beta Imager 2000Z Digi-
tal Beta Imaging System (Biospace, France). After the gas
was well mixed and a homogenous state was reached,
exposure of the slides for 20 h yielded high-quality
images. A [3H]Microscale (American Radiolabeled Chem-
icals, St Louis, Missouri) was counted simultaneously as a
reference for total radioactivity quantitative analysis.
Quantitative analysis was performed using the program
Beta-Vision Plus (BioSpace, France) for anatomical
regions of interest.
Statistical analysis
The receptor-bound radioligand binding apparent densi-
ties were calculated as described previously using the
specific activity of each radioligand expressed as fmol/mg
tissue.35,36 The experimenter was blinded to all conditions
during the analysis. Comparison of receptor densities was
analyzed using an unpaired Student’s t test. The correla-
tion between receptor binding densities across different
brain regions was assessed using Pearson product-mo-
ment correlation coefficient.
RESULTS
Quantitative analysis of TSPO binding
The sensitivity limit of the Beta Imager 2000Z Digital
Beta Imaging System is 0.07 dpm/mm2. A tritium
Table 1. Demographic details, clinical, and pathological features of cases.
Case # Age (years) Gender Brain weight (g) PMI (h) Braak tangle Braak amyloid Exp CDR Diagnosis
1 77 F 1410 10 1 A 0 Con
2 91.6 F 1310 16 2 0 0 Con
3 92.1 F 1120 6 0 0 0 Con
4 91.6 F 1220 16 2 A 0 Con
5 79 F 1100 25 1 A 0 Con
6 90 M 1150 10 4 A 0 Con
7 84 M 1010 5.5 1 B 0 Con
8 91 M 1170 8.5 1 A 0 Con
9 84 M 1180 21 5 C 3 DLB
10 82 M 1200 16.25 5 C 3 DLB
11 84 F 950 5 3 A 1 DLB
12 79 F 940 21.25 6 C 3 DLB
13 91 F 940 18 6 C 3 DLB
14 80 F 1130 7 6 C 3 AD
15 83 F 950 6.45 6 C 3 AD
16 74 M 1120 4 6 C 3 AD
17 88 F 1050 6 6 C 3 AD
18 88 F 785 21 6 C 3 AD
19 86 F 1250 7 5 C 1 AD
20 81 F 1050 8.5 4 C 3 AD
AD, Alzheimer’s disease; Con, Control; DLB, Dementia with Lewy Bodies; PMI, Post-mortem interval; Exp CDR, Estimated clinical dementia rating
at expiration.
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standard was counted with each set of slides, the [3H]
Microscale contains multiple strips with a known amount
of radioactivity (ranging from 0 to 36.3 nCi/mg) and was
used to create a standard curve. In each case the standard
curve had a correlation coefficient (R) greater than 0.99.
The binding density of TSPO was determined by quanti-
tative autoradiography using 2 nmol/L [3H]PK11195 and
[3H]PBR28 (Fig. 1). The nonspecific binding was deter-
mined by using the high affinity cold compound and was
much higher with [3H]PK11195 than [3H]PBR28 (Figs. 2,
3, 4C and D). TSPO receptor density values in different
brain regions are summarized in Table 2.
TSPO densities in multiple brain regions of
healthy control cases measured by [3H]
PK11195 and [3H]PBR28
In order to verify the consistency of [3H]PK11195 and
[3H]PBR28 binding, we first compared TSPO densities
measured by these two radioligands in different brain
regions of control cases. Although the nonspecific binding
of PK11195 is higher than [3H]PBR28, the TSPO densities
measured by [3H]PK11195 and [3H]PBR28 showed no
significant differences across all the brain regions mea-
sured (Fig. 1). The regional distribution of TSPO in
control brains was similar, whether measured by [3H]
PK11195 or [3H]PBR28: the lowest measured TSPO den-
sity level was in the RN, a modest level was found in the
striatum (putamen and caudate), and the highest levels
were found in the frontal cortex, thalamus, and SN
(Fig. 1 and Table 2).
TSPO density changes in multiple brain
regions of AD, DLB cases compared to age-
matched controls
Frontal cortex
A similar binding pattern of [3H]PK11195 and [3H]
PBR28 was observed in the frontal cortex; TSPO bind-
ing was mainly located in the grey matter, whereas
TSPO binding in the white matter is relatively lower
than in the grey matter (Fig. 2A and B). The non-
specific binding of [3H]PBR28 is lower than the bind-
ing of [3H]PK11195 (Fig. 2C and D). TSPO binding
densities were similar for [3H]PK11195 and [3H]PBR28
in the frontal cortex of the control cases and the AD
and DLB cases. Compared to the age-matched controls,
no significant difference in cortical TSPO densities
between control and AD or DLB cases was found by
Figure 1. Comparison of translocator protein (TSPO) densities in the normal aged post mortem human brain measured by [3H]PK11195 and [3H]
PBR28. Quantitative analysis of 2 nmol/L [3H]PK11195 and 2 nmol/L [3H]PBR28 binding in multiple brain regions of aged human healthy control
cases (n = 8, aged 77–92 years). Non-specific binding was determined by the presence of 1 µmol/L unlabeled PBR28 for [3H]PK11195 and
1 µmol/L PK11195 for [3H]PBR28. Specific receptor binding densities (fmol/mg) were calculated by subtracting nonspecific binding from total
binding. Data was calculated from the average of 2–4 adjacent sections of each case and presented as mean  SEM. Th, Thalamus; SN,
Substantia nigra; Fr, Frontal cortex; Cd, Caudate; Pu, Putamen; RN, Red nucleus.
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either [3H]PK11195 or [3H]PBR28 autoradiography
(Fig. 2F).
Striatum
TSPO was found to be homogeneously distributed in the
striatum, including in the putamen and the caudate;
whereas binding in the internal capsule was very low as
measured by both [3H]PK11195 and [3H]PBR28 (Fig. 3A
and B). The nonspecific binding was lower with [3H]
PBR28 than with [3H]PK11195 (Fig. 3C and D). TSPO
density as measured by [3H]PK11195 was higher than
that measured with [3H]PBR28 both in the putamen and
the caudate, but no significant differences in striatal
TSPO densities were found between the control and the
AD or DLB cases when measured using either [3H]
PK11195 or [3H]PBR28 autoradiography (Fig. 3F and G).
Thalamus
TSPO was abundantly distributed in the thalamus and
the density as measured by [3H]PK11195 and [3H]PBR28
gave similar results (Fig. 4A, B and H). However, non-
specific binding of [3H]PK11195 was higher than that of
[3H]PBR28 in the thalamus (Fig. 4C and D). The
decreased trend of thalamic TSPO binding in AD and
DLB compared to the age-matched controls was found
not to be significantly different when measured using
[3H]PK11195 and [3H]PBR28 autoradiography (Fig. 4H).
Red nucleus
TSPO density was the lowest in the RN compared to the other
regions (Fig. 4G; Table 2). There were no significant changes
in the TSPO densities in the red nucleus between the control
Figure 2. [3H]PBR28 and [3H]PK11195 quantitative autoradiographic analysis of translocator protein (TSPO) density in the frontal cortex of AD,
DLB and age-matched healthy control cases. Representative autoradiograms show total and nonspecific binding of [3H]PBR28 (A, C) and [3H]
PK11195 (B, D) in frontal cortex sections. [3H]Microscale standards (ranging from 0 to 36.3 nCi/mg) were also counted (E). Quantitative analysis
of TSPO density in frontal cortex (F) using [3H]PBR28 and [3H]PK11195.
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and the AD or DLB cases when measured using either [3H]
PK11195 or [3H]PBR28 autoradiography (Fig. 4G).
TSPO density decreased in the substantia
nigra of AD, DLB cases compared to age-
matched control
There was a high level of TSPO in the SN in control cases
as measured by [3H]PK11195 and [3H]PBR28 (Figure 1;
Fig. 4A and B; Table 2). Compared to the controls, the
TSPO density was significantly decreased in AD as mea-
sured by both [3H]PBR28 (P = 0.01) and [3H]PK11195
(P = 0.02). A significant reduction in TSPO density was
also found for DLB cases compared to that of the age-
matched control measured by either [3H]PBR28
(P = 0.04) or [3H]PK11195 (P = 0.03) (Fig. 4F). TSPO
density in the SN measured using either [3H]PK11195 or
[3H]PBR28 was similar; a relatively higher nonspecific
binding was found with [3H]PK11195 than [3H]PBR28
(Fig. 4C and D).
Regional correlation of TSPO density in the
frontal cortex, striatum and substantia
nigra measured by [3H]PBR28
TSPO density in the frontal cortex significantly correlated
with density in the striatal regions (both putamen and
caudate); there was also a significate correlation between
Figure 3. Quantitative autoradiographic analysis of translocator protein (TSPO) density in the striatum of AD, DLB, and age-matched healthy
control cases. Representative autoradiograms show total binding and nonspecific binding of [3H]PBR28 (A, C) and [3H]PK11195 (B, D). CNS
anatomical regions are identified on the control striatal section (A): (1) caudate, (2) putamen, (3) internal capsule (IC). [3H]Microscale standards
(ranging from 0 to 36.3 nCi/mg) were also counted (E). Quantitative analysis of TSPO density in the putamen (F) and the caudate (G) measured
using [3H]PBR28 and [3H]PK11195.
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TSPO density in the putamen and density in the caudate
(Fig. 5A). No such correlations were found between the
SN and the frontal cortex, putamen, or caudate (Fig. 5B);
this is due to the significant correlation in TSPO density
in the SN of AD and DLB cases.
Discussion
In this study, the TSPO density was measured in multiple
brain regions of postmortem human brains in a group of
late stage AD and DLB cases that had a heavy burden of
Figure 4. [3H]PBR28 and [3H]PK11195 quantitative autoradiographic analysis of translocator protein (TSPO) density in the substantia nigra,
thalamus and red nucleus of AD, DLB, and age-matched healthy control cases. Representative autoradiograms show total binding and nonspecific
binding of [3H]PBR28 (A, D) and [3H]PK11195 (B, C). CNS anatomical regions are identified on the control section (A): (1) substantia nigra, (2) red
nucleus, (3) thalamus. [3H]Microscale standards (ranging from 0 to 36.3 nCi/mg) were also counted (E). Quantitative analysis of TSPO density in
the substantia nigra (F), red nucleus (G), and thalamus (H). *P < 0.05 compared to control.
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amyloid beta and NFTs. TSPO density was measured by
quantitative autoradiography using two different tritiated
ligands, [3H]PK11195 and [3H]PBR28. Brain weight,
Braak amyloid, and Braak NFTs stages of AD and DLB
cases were significantly different from those of age-
matched healthy controls. However, TSPO density
appeared to be at a similar level in multiple brain regions
including: frontal cortex, striatum, thalamus and red
nucleus. Furthermore, we discovered that TSPO density
was significantly decreased in the SN of AD and DLB
cases.
TSPO density was measured by [3H]PK11195 and [3H]
PBR28 in this study. Although renewed efforts are still
ongoing to develop and evaluate more potent and specific
TSPO radiotracers,37–41 [3H]PK11195 is widely used, and
is accepted as the “gold standard”, to measure TSPO den-
sity both in vitro and in vivo. However, we observed a
relatively high nonspecific binding level and lower signal-
Table 2. [3H]PBR28 and [3H]PK11195 binding densities in the late stage Alzheimer’s Disease (AD) (n = 7) and Dementia with Lewy Bodies (DLB)
(n = 5) patients (fmol/mg) compared to age-matched control (n = 7).
[3H]PBR28 [3H]PK11195
Control DLB AD Control DLB AD
Fr 418  46 440  48 451  61 422  30 403  41 444  42
Pu 297  33 280  30 245  42 372  45 401  8 368  42
Cd 302  34 315  48 241  30 360  31 430  27 392  29
SN 432  63 291  20* 258  26* 405  64 245  27* 243  29*
Th 459  100 298  15 314  59 403  93 265  23 345  48
RN 180  23 184  10 152  18 183  28 134  19 156  23
Fr, Frontal cortex; Pu, Putamen; Cd, Caudate; SN, Substantia nigra; Th, Thalamus; RN, Red nucleus.
Data presented as mean value  SEM. *P < 0.05 compared to control.
Figure 5. Regional correlation of translocator protein (TSPO) density measured by [3H]PBR28. Regional correlations in TSPO density measured
using [3H]PBR28 were performed for all the cases. Significant correlation of TSPO densities was found between the frontal cortex with the
putamen and the caudate and between the putamen and the caudate (A). Regional correlation of TSPO densities between substantia nigra with
frontal cortex, the putamen, and the caudate are shown in B.
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noise ratio using [3H]PK11195. [11C]PBR28 is an
improved TSPO radioligand with higher binding affinity
and selectivity42–47 which has been successfully used to
measure TSPO density in cerebral ischemia48 as well as in
multiple sclerosis.49 TSPO densities measured by [3H]
PK11195 and [3H]PBR28 in this study appeared to be at
similar level, indicating a consistency of measurement for
these two radioligands. Human subjects can have variable
binding levels in PBR28 PET and autoradiography human
study due to polymorphism in the 18 kDa protein;
codominance of the trait results in trimodal distribu-
tion.50–52 This is an important issue considering the
reduction in TSPO density as measured by [3H]PBR28 in
this study, however, it is unlikely that this reduction in
TSPO density can be attributed to polymorphism. Two
reasons indicate this: (1) In this study the reduction of
TSPO density as measured by [3H]PBR28 was only slight
(15–20% compared to that of age-matched control cases),
but low affinity binders (a single nucleotide polymor-
phism (SNP) of PBR, Ala147Thr) have an affinity is 10-
fold lower and while mixed affinity binders show ~ 50%
reduction50 compared to the wild type; and (2) TSPO
density measured by [3H]PK11195 was at the same level
as that of [3H] PBR28 and no low binder phenomenon
has been reported for [3H]PK11195. The cases used for
our study can be safely assumed to consist of high affinity
binders or mixed affinity binders as described previ-
ously.45,51,52
No significant changes were found in TSPO density of
the frontal cortex, striatum, thalamus, or red nucleus in
late stage AD and DLB cases compared to that of age-
matched control cases. This is different from most previ-
ous PET or autoradiography studies, in which an increase
in TSPO density was usually found in the early and mid-
dle stage of AD. However, this is in line with a previous
PET study using [11C]PK11195 which showed no signifi-
cant changes of TSPO density in AD compared to that of
an age-matched control.9 It is also in line with another
PET study using [11C]vinpocetine, which found a signifi-
cant increase in TSPO density in the brain of aged
healthy controls and aged AD patients compared to that
found in young healthy control subjects, but no signifi-
cant difference between aged AD patients and age-
matched controls.11 Our findings, along with other results
of previous studies, indicate that there may be a different
pattern of changes in TSPO between early and late stage
AD. In early stage AD, TSPO increases as a marker of
microglial activation; whereas in late stage AD, this
increase in TSPO density disappears. This may reflect the
different states of microglia at different AD stages. This is
interesting when considering recent findings showing that
there were more dysfunctional microglia in the AD brain
than in non-demented, amyloid-free control subjects29
and that Tau pathology was co-localized with dystrophic
microglial cells.30 It is reasonable to deduce that with the
progression of disease, the increase in TSPO density dur-
ing early stage AD can become slower because of micro-
glial dysfunction, which leads to no significant difference
in TSPO density during late stage AD. This different tem-
poral curve of TSPO density changes between the normal
aging process and the AD brain may reflect a different
microglia reaction pattern. In the AD brain, it seems that
microglia are more predisposed to become dystrophic
after initial activation than in the normally aging brain,
in which a decrease in the up-regulation of MHCП
expression on microglial cell surface, an indicator of
microglia activation, was only observed at age> 80 years
old in human post-mortem brain.53
TSPO density was found to be significantly decreased
in the SN, indicating a significant microglia dystrophy
occurred in this region during the late stages of AD and
DLB. This is different from previous reports indicating
microglial activation in the SN during early stage DLB
and AD cases.54 It is not surprising that decreased TSPO
density, which may be a marker of microglia dystrophy,
was also found in the SN of the AD brain. This is because
a type of SN pathology which includes neuronal loss,
Lewy bodies, and NFT has been proven to be present in
AD.55–62 The significant reduction in TSPO density of the
SN in the late stages AD and DLB is an interesting phe-
nomenon which may imply an interaction between
microglial dystrophy and neuronal loss in the same
region. On one hand, dystrophic microglia can accelerate
neuronal loss through the dysfunction of phagocytosis
leading to more deposition of NFT and amyloid beta as
well as through microglia-mediated neuroinflammation,
which is well documented in dystrophic microglial cells.
On the other hand, significant neuronal death in the SN
may also prompt microglial dystrophy, although this pos-
sibility needs to be elucidated further.
It is more likely that the reduction in TSPO density of
the SN in AD and DLB cases is mainly attributed to the
loss of microglial cells, but it could also be due to down-
regulation of TSPO on the mitochondrial membrane, or a
decreased turnover rate of mitochondria in dystrophic
microglia. The complete function of TSPO is not fully
understood, but it has been reported that increased
expression of TSPO can protect cells from apoptosis
through the regulation of the mitochondrial permeability
transition pore complex.2,63–65 In addition, TSPO can
mediate protective effects against ROS damage.66 This is
important because oxidative stress and mitochondrial dys-
function are thought to be closely related to neurodegen-
erative diseases.67–70 Taken together, the reduction in
TSPO density in the late stages of AD and DLB found in
this study may not only reflect the loss of microglial cells
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but also may be a marker of dysfunction of mitochondria
in microglial cells, which in turn contributes to microglia
apoptosis and eventual neurodegeneration.71
In summary, this study provides quantitative information
about TSPO changes in late stage AD and DLB brains,
showing different patterns of change compared to that seen
in early stage ADs. A presence of change or reduction in
TSPO density may reflect dystrophy, senescence and death,
or dysfunction of mitochondria in the microglia, in turn
contributing to the neuronal loss in the late stage AD. Fur-
thermore, the different pattern of change seen for TSPO
density between early and late stage AD may indicate the
importance of dynamic monitoring of TSPO through clini-
cal PET imaging; not the initial increase, but rather the
decrease in the upregulation of TSPO density may herald
the progression of neurodegeneration.
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